Literature DB >> 19673075

Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.

Roshan Kukreja1, Tzuu-Wang Chang, Shuowei Cai, Paul Lindo, Stephen Riding, Yu Zhou, Easwaran Ravichandran, Bal Ram Singh.   

Abstract

Botulinum neurotoxins (BoNTs) constitute a family of seven structurally similar but antigenically distinct proteins produced by different strains of Clostridium botulinum. Type A botulinum neurotoxin (BoNT/A) is produced along with 6 neurotoxin associated proteins (NAPs) including hemagglutinin (Hn-33) through polycistronic expression of a clustered group of genes to form a complex (BoNT/AC). The presence of NAPs enhances the oral toxicity of the neurotoxin significantly. Hn-33 makes up the largest fraction of NAPs in BoNT/AC and strongly protects BoNT/A against proteases of the GI tract. BoNT in its complex form is also used in therapeutic and cosmetic applications to treat several neuromuscular disorders. In this study immunological reactivity of BoNT/A in its purified and complex forms, neurotoxin associated proteins, and Hn-33 have been examined using enzyme-linked immunosorbent assay (ELISA). Antibodies raised against the whole complex reacted 60 times better with the complex and 35 times better with Hn-33 and NAPs compared to the purified neurotoxin suggesting stronger immunogenicity of NAPs over that of purified neurotoxin and a higher potential of BoNT/AC and its associated proteins to induce host immune response. This observation also suggests that Hn-33 and other NAPs could potentially be employed as adjuvants for development of vaccines against botulism and could be a good surrogate for botulinum diagnostics. ELISA binding curves of BoNT/AC and BoNT/A with antibodies raised against BoNT/A indicate that BoNT/A in its purified and complex forms induces equal immunogenic response and a 2.5-fold higher immunogenic response compared to BoNT/A light and heavy chains. We have also discovered a new protein, an intimin analog, present within the complex preparation of BoNT/A which shows dramatically high immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673075     DOI: 10.1016/j.toxicon.2009.01.017

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  23 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

2.  Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.

Authors:  Ali Sayadmanesh; Firouz Ebrahimi; Abbas Hajizade; Mosayeb Rostamian; Hani Keshavarz
Journal:  Iran Biomed J       Date:  2013

3.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

Review 4.  Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Authors:  Oussama El Yazami Adli; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

5.  [Cutaneous granulomatous reactions at botulinum neurotoxin A injection sites: First manifestation of systemic sarcoidosis].

Authors:  V G Herbert; N Blödorn-Schlicht; A Böer-Auer; V Getova; V Steinkraus; K Reich; K Breuer
Journal:  Hautarzt       Date:  2015-11       Impact factor: 0.751

6.  Flu-like symptoms and associated immunological response following therapy with botulinum toxins.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic; Jordan Feld
Journal:  Neurotox Res       Date:  2013-05-16       Impact factor: 3.911

7.  Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain.

Authors:  Anne-Marie Bryant; Jenny Davis; Shuowei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2013-02       Impact factor: 2.371

8.  Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.

Authors:  Anne-Marie Bryant; Shuowei Cai; Bal Ram Singh
Journal:  Toxicon       Date:  2013-06-28       Impact factor: 3.033

9.  Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.

Authors:  Kruti B Patel; Shuowei Cai; Michael Adler; Brajendra K Singh; Virinder S Parmar; Bal Ram Singh
Journal:  Appl Environ Microbiol       Date:  2018-11-30       Impact factor: 4.792

Review 10.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.